aTyr Pharma Announces Achievement of Development Milestone by Partner Kyorin Pharmaceutical, Co., Ltd.
$10M milestone payment triggered by advancement of clinical program in Japan. Multiple centers in the U.S. and Japan are now...
Month: February 2023
Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target
SAN CARLOS, Calif., and MONROVIA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology...
Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients
-- Topline Results Expected in Q4 2023 -- -- LYR-220 is Lyra’s Second Product Candidate, Following LYR-210 in Surgically-Naïve CRS...
Kane Biotech Announces Extension of Term of Credit Facility
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Feb. 06, 2023 (GLOBE...
Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody
BOSTON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and...
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
ONA-XR initial data signals positive clinical activity and confirmed tumor shrinkage ONA-XR continues to be safe and well-tolerated PHILADELPHIA, Feb....
VitalHub Announces a Multi-Year Licensing of the TREAT Client Information System to Habitat Services
TORONTO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) (OTCQX:VHIBF) is pleased to announce...
Clearside Biomedical Announces Leadership Team Update
ALPHARETTA, Ga., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to...
Arbutus to Participate in Three Upcoming Investor Conferences
WARMINSTER, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive...
Inozyme Pharma to Host Virtual Investor and Analyst Event on Feb. 16, 2023
- Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency (PXE)...
HeartSciences Granted Key Israeli International Patent for its MyoVista® Wavelet Technology Utilizing Artificial Intelligence (AI) for Early Detection of Heart Disease
Israeli patent covers a country known as a hotbed for medical device innovationSouthlake, Texas, Feb. 06, 2023 (GLOBE NEWSWIRE) --...
Clinical Trials – Outlook And Trends For 2023
Clinical trials for testing potential drugs, procedures, or devices have evolved over hundreds of years. Scientists use clinical trials on...
Natural VS Safe Ingredients: What Matters When it Comes to Our Beauty Products?
By Michael Ambacher We all want to look and feel our best – but finding the right products to support...
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders
PALO ALTO, Calif., Feb. 04, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento...
City of Vacaville Introduces Next Generation to Biotechnology and Advanced Manufacturing
Vacaville high school students explore local career opportunities to honor National Career Technical Education Month Students at ICON Aircraft Students...
Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms and Provides Specific Instruction to Continental Stock Transfer & Trust Company Regarding the Dividend of Scilex Holding Company Common Stock
SAN DIEGO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today distributed dividend confirmation statements to...
Psychedelic-Assisted Therapies Allowed in Australia Through Special Access Scheme
SAN JOSE, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- The Therapeutic Goods Administration (TGA) in Australia announced today that they...
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®
In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to...
Bioasis Announces AGM Results and Provides Update on Financial Position
NEW HAVEN, Conn., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset...
How Can We Create Accurate Digital Twins of the Human Vasculature?
By Dr. Amanda Randles, Ph.D. — National Academy of Inventors Fellow & Alfred Winborne and Victoria Stover Mordecai Assistant Professor...